Defective DNA mismatch repair influences expression of endometrial carcinoma biomarkers

Ekene I. Okoye, Amanda Bruegl, Bryan Fellman, Rajyalakshmi Luthra, Russell R. Broaddus

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Endometrial endometrioid carcinomas are related to estrogen excess and express estrogen and progesterone receptors. However, hormone receptor expression can be variable from tumor to tumor, and this variability is not always explained by differences in tumor grade. Variable expression of other biomarkers that may be used in the diagnostic work-up of endometrial cancer has also been noted. We hypothesized that mismatch repair (MMR) defects may contribute to this variability. A total of 411 unselected endometrial carcinomas were evaluated for immunohistochemical expression of DNA MMR proteins and MLH1 methylation. Loss of immunohistochemical expression of MLH1, MSH2, MSH6, or PMS2 was defined as MMR deficient; positive expression was defined as MMR intact. A case-control cohort of 80 Grade 2 endometrioid carcinomas was selected from this set (40 MMR deficient, 40 MMR intact). Cases were matched for histotype, grade, and age. Estrogen receptor, progesterone receptor, CK7, CK20, and Pax-8 immunohistochemistry was evaluated. The median percentage of CK7 + tumor cells was significantly lower in the MMR deficient group compared with the MMR intact group. The mean percentage of tumor cells exhibiting estrogen receptor expression was similar in both the MMR-deficient and MMR intact groups. However, there was greater variability in the MMR-deficient group. Our study shows that MMR defects influence the expression of clinically important biomarkers for endometrioid-type endometrial carcinoma as decreased cytokeratin 7 expression is more commonly associated with MMR deficiency.

Original languageEnglish (US)
Pages (from-to)8-15
Number of pages8
JournalInternational Journal of Gynecological Pathology
Volume35
Issue number1
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

DNA Mismatch Repair
Endometrial Neoplasms
Biomarkers
Endometrioid Carcinoma
Estrogen Receptors
Progesterone Receptors
Neoplasms
Keratin-7
Methylation
Estrogens
Immunohistochemistry

Keywords

  • Cytokeratin 7
  • Endometrial carcinoma
  • Endometrioid carcinoma
  • Estrogen receptor
  • Microsatellite instability
  • Mismatch repair genes

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Obstetrics and Gynecology

Cite this

Defective DNA mismatch repair influences expression of endometrial carcinoma biomarkers. / Okoye, Ekene I.; Bruegl, Amanda; Fellman, Bryan; Luthra, Rajyalakshmi; Broaddus, Russell R.

In: International Journal of Gynecological Pathology, Vol. 35, No. 1, 01.01.2016, p. 8-15.

Research output: Contribution to journalArticle

Okoye, Ekene I. ; Bruegl, Amanda ; Fellman, Bryan ; Luthra, Rajyalakshmi ; Broaddus, Russell R. / Defective DNA mismatch repair influences expression of endometrial carcinoma biomarkers. In: International Journal of Gynecological Pathology. 2016 ; Vol. 35, No. 1. pp. 8-15.
@article{761eae9d0b5e47e798543ed6082495ce,
title = "Defective DNA mismatch repair influences expression of endometrial carcinoma biomarkers",
abstract = "Endometrial endometrioid carcinomas are related to estrogen excess and express estrogen and progesterone receptors. However, hormone receptor expression can be variable from tumor to tumor, and this variability is not always explained by differences in tumor grade. Variable expression of other biomarkers that may be used in the diagnostic work-up of endometrial cancer has also been noted. We hypothesized that mismatch repair (MMR) defects may contribute to this variability. A total of 411 unselected endometrial carcinomas were evaluated for immunohistochemical expression of DNA MMR proteins and MLH1 methylation. Loss of immunohistochemical expression of MLH1, MSH2, MSH6, or PMS2 was defined as MMR deficient; positive expression was defined as MMR intact. A case-control cohort of 80 Grade 2 endometrioid carcinomas was selected from this set (40 MMR deficient, 40 MMR intact). Cases were matched for histotype, grade, and age. Estrogen receptor, progesterone receptor, CK7, CK20, and Pax-8 immunohistochemistry was evaluated. The median percentage of CK7 + tumor cells was significantly lower in the MMR deficient group compared with the MMR intact group. The mean percentage of tumor cells exhibiting estrogen receptor expression was similar in both the MMR-deficient and MMR intact groups. However, there was greater variability in the MMR-deficient group. Our study shows that MMR defects influence the expression of clinically important biomarkers for endometrioid-type endometrial carcinoma as decreased cytokeratin 7 expression is more commonly associated with MMR deficiency.",
keywords = "Cytokeratin 7, Endometrial carcinoma, Endometrioid carcinoma, Estrogen receptor, Microsatellite instability, Mismatch repair genes",
author = "Okoye, {Ekene I.} and Amanda Bruegl and Bryan Fellman and Rajyalakshmi Luthra and Broaddus, {Russell R.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1097/PGP.0000000000000193",
language = "English (US)",
volume = "35",
pages = "8--15",
journal = "International Journal of Gynecological Pathology",
issn = "0277-1691",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Defective DNA mismatch repair influences expression of endometrial carcinoma biomarkers

AU - Okoye, Ekene I.

AU - Bruegl, Amanda

AU - Fellman, Bryan

AU - Luthra, Rajyalakshmi

AU - Broaddus, Russell R.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Endometrial endometrioid carcinomas are related to estrogen excess and express estrogen and progesterone receptors. However, hormone receptor expression can be variable from tumor to tumor, and this variability is not always explained by differences in tumor grade. Variable expression of other biomarkers that may be used in the diagnostic work-up of endometrial cancer has also been noted. We hypothesized that mismatch repair (MMR) defects may contribute to this variability. A total of 411 unselected endometrial carcinomas were evaluated for immunohistochemical expression of DNA MMR proteins and MLH1 methylation. Loss of immunohistochemical expression of MLH1, MSH2, MSH6, or PMS2 was defined as MMR deficient; positive expression was defined as MMR intact. A case-control cohort of 80 Grade 2 endometrioid carcinomas was selected from this set (40 MMR deficient, 40 MMR intact). Cases were matched for histotype, grade, and age. Estrogen receptor, progesterone receptor, CK7, CK20, and Pax-8 immunohistochemistry was evaluated. The median percentage of CK7 + tumor cells was significantly lower in the MMR deficient group compared with the MMR intact group. The mean percentage of tumor cells exhibiting estrogen receptor expression was similar in both the MMR-deficient and MMR intact groups. However, there was greater variability in the MMR-deficient group. Our study shows that MMR defects influence the expression of clinically important biomarkers for endometrioid-type endometrial carcinoma as decreased cytokeratin 7 expression is more commonly associated with MMR deficiency.

AB - Endometrial endometrioid carcinomas are related to estrogen excess and express estrogen and progesterone receptors. However, hormone receptor expression can be variable from tumor to tumor, and this variability is not always explained by differences in tumor grade. Variable expression of other biomarkers that may be used in the diagnostic work-up of endometrial cancer has also been noted. We hypothesized that mismatch repair (MMR) defects may contribute to this variability. A total of 411 unselected endometrial carcinomas were evaluated for immunohistochemical expression of DNA MMR proteins and MLH1 methylation. Loss of immunohistochemical expression of MLH1, MSH2, MSH6, or PMS2 was defined as MMR deficient; positive expression was defined as MMR intact. A case-control cohort of 80 Grade 2 endometrioid carcinomas was selected from this set (40 MMR deficient, 40 MMR intact). Cases were matched for histotype, grade, and age. Estrogen receptor, progesterone receptor, CK7, CK20, and Pax-8 immunohistochemistry was evaluated. The median percentage of CK7 + tumor cells was significantly lower in the MMR deficient group compared with the MMR intact group. The mean percentage of tumor cells exhibiting estrogen receptor expression was similar in both the MMR-deficient and MMR intact groups. However, there was greater variability in the MMR-deficient group. Our study shows that MMR defects influence the expression of clinically important biomarkers for endometrioid-type endometrial carcinoma as decreased cytokeratin 7 expression is more commonly associated with MMR deficiency.

KW - Cytokeratin 7

KW - Endometrial carcinoma

KW - Endometrioid carcinoma

KW - Estrogen receptor

KW - Microsatellite instability

KW - Mismatch repair genes

UR - http://www.scopus.com/inward/record.url?scp=84952683292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952683292&partnerID=8YFLogxK

U2 - 10.1097/PGP.0000000000000193

DO - 10.1097/PGP.0000000000000193

M3 - Article

C2 - 25851713

AN - SCOPUS:84952683292

VL - 35

SP - 8

EP - 15

JO - International Journal of Gynecological Pathology

JF - International Journal of Gynecological Pathology

SN - 0277-1691

IS - 1

ER -